Stammdaten
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Unternehmen & Branche
| Name | GRI Bio, Inc. |
|---|---|
| Ticker | GRI |
| CIK | 0001824293 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 199.607 USD |
| Beta | -1,24 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -11,956,000 | -121.80 | 8,666,000 | 6,008,000 | |
| 2025-09-30 | 10-Q | -3,359,000 | -1.28 | 4,782,000 | 1,993,000 | |
| 2025-06-30 | 10-Q | -2,892,000 | -1.31 | 5,675,000 | 3,322,000 | |
| 2025-03-31 | 10-Q | -3,046,000 | -5.80 | 4,042,000 | 1,205,000 | |
| 2024-12-31 | 10-K | -8,207,000 | -###.## | 5,739,000 | 4,032,000 | |
| 2024-09-30 | 10-Q | -2,123,000 | -11.42 | 5,459,000 | 3,660,000 | |
| 2024-06-30 | 10-Q | -2,250,000 | -61.85 | 7,031,000 | 4,719,000 | |
| 2024-03-31 | 10-Q | -1,887,000 | -101.05 | 4,587,000 | 2,798,000 | |
| 2023-12-31 | 10-K | -13,037,000 | -###.## | 2,956,000 | 259,000 | |
| 2023-09-30 | 10-Q | -2,137,000 | -65.78 | 4,404,000 | 2,227,000 | |
| 2023-06-30 | 10-Q | -6,746,000 | -239.37 | 5,642,000 | 4,038,000 | |
| 2023-03-31 | 10-Q | -2,150,000 | -15.04 | 2,097,000 | -3,230,000 | |
| 2022-12-31 | 10-K | -3,217,000 | -24.95 | 383,000 | -1,625,000 | |
| 2022-09-30 | 10-Q | -351,000 | -0.39 | 5,569,000 | -5,706,000 | |
| 2022-06-30 | 10-Q | -295,000 | -0.35 | 8,007,000 | -5,445,000 | |
| 2022-03-31 | 10-Q | 0 | -302,000 | -11.62 | 5,944,000 | -5,150,000 |
| 2021-12-31 | 10-K | 0 | -9,303,000 | -1.42 | 8,335,000 | -4,848,000 |
| 2021-09-30 | 10-Q | 0 | -1,257,000 | -0.18 | 10,140,000 | 8,729,000 |
| 2021-06-30 | 10-Q | 0 | -2,312,000 | -0.34 | 11,647,000 | 9,853,000 |
| 2021-03-31 | 10-Q | 0 | -2,638,000 | -0.46 | 14,600,000 | 12,027,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.